Microba Life Sciences Limited (ASX:MAP)
Australia · Delayed Price · Currency is AUD | Market Cap | 46.89M -43.4% |
| Revenue (ttm) | 14.90M -11.8% |
| Net Income | -19.75M |
| EPS | -0.04 |
| Shares Out | 608.96M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 178,128 |
| Average Volume | 488,843 |
| Open | 0.0780 |
| Previous Close | 0.0770 |
| Day's Range | 0.0750 - 0.0780 |
| 52-Week Range | 0.0670 - 0.1750 |
| Beta | 2.03 |
| RSI | 48.36 |
| Earnings Date | Apr 29, 2026 |
About Microba Life Sciences
Microba Life Sciences Limited provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. It offers pathology, therapeutics, and diagnostics services based on the human gut microbiome; Databank, for discovery of therapeutic leads, consumer health innovations, and diagnostic biomarkers; and data-driven therapeutics platform that develops novel monoclonal microbial cell therapies for inflammatory bowel di... [Read more]
Financial Performance
In fiscal year 2025, Microba Life Sciences's revenue was 15.67 million, an increase of 29.60% compared to the previous year's 12.09 million. Losses were -14.94 million, -25.07% less than in 2024.
Financial StatementsNews
Microba Life Sciences Earnings Call Transcript: Q3 2026
Core testing revenue grew 99% year-on-year, with strong adoption in Australia and the UK and a robust pipeline of enterprise contracts. New product launches and clinical integration are set to drive further growth, while positive sector trial results boost the value of therapeutic assets.
Microba Life Sciences Earnings Call Transcript: Q2 2026
Core clinical test volumes grew 90% year-on-year, with strong adoption in Australia and the UK, and a full transition to high-margin products. Operational efficiencies, AI integration, and positive sector clinical trial readouts position the business for break-even and potential upside from therapeutics deals.
Microba Life Sciences Earnings Call Transcript: Q1 2026
Strong core test growth and disciplined cost management offset legacy product wind-down, with revenue up 42% year-on-year excluding discontinued products. On track for regional break-even and poised for clean revenue growth from Q3, with major clinical and partnering catalysts ahead.
Microba Life Sciences Earnings Call Transcript: Q4 2025
Record core test growth drove FY2025 revenue up 30% year-on-year to $15.67 million, with strong adoption in Australia and the UK. FY2026 targets over 24,000 core tests and regional breakeven, while therapeutics shift to deal-making with two catalysts expected before year-end.
Microba Life Sciences Transcript: Investor Update
Revenue guidance narrowed to AUD 15.4–16 million for FY, with over 145% core product growth and break-even targeted in Australia and the UK by FY2026. AUD 14.5 million was raised to fund expansion, leveraging key partnerships and a product-led growth strategy.
Microba Life Sciences Earnings Call Transcript: Q3 2025
Core diagnostic test volumes surged 240% year-on-year, with record growth in Australia and the U.K. Landmark clinical results for MetaPanel in IBD and a major partnership were announced. The therapeutics business shifted to a capital-light, partnering model.
Microba Life Sciences Earnings Call Transcript: Q2 2025
Quarterly revenue surged 102% year-over-year to AUD 4.43 million, with MetaXplore test sales in Australia up 195% and strong momentum in both diagnostics and therapeutics. Expansion in the UK and robust partnerships underpin a positive outlook for continued growth.
Microba Life Sciences Earnings Call Transcript: Q1 2025
Revenue surged 239% year on year to AUD 3.65 million, driven by strong MetaXplore sales in Australia and a successful UK launch. Strategic hires and expanded sales force support continued growth, with robust cash reserves and advancing therapeutics pipeline.
Microba Life Sciences Earnings Call Transcript: Q4 2024
Revenue surged 123% year-over-year to AUD 12 million, driven by strong diagnostic test adoption and UK expansion. Therapeutic programs advanced, including a completed Phase 1 trial and a major autoimmune discovery milestone.